Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MDX-1100 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| MDX-1100 | EXPERIMENTAL | MDX-1100 10 mg/kg administered i.v. over 60 minutes on days 1, 15, 29, 43, 57, and 71 |
| Placebo | PLACEBO_COMPARATOR | Placebo (saline) administered i.v. over 60 minutes on days 1, 15, 29, 43, 57, and 71 |
| 1 | EXPERIMENTAL | patients will receive active MDX-1100 |
| Name | Type | Description |
|---|---|---|
| MDX-1100 | DRUG | MDX-1100 10 mg/kg i.v. over 60 minutes on days 1, 15, 29, 43, 57 and 71 |
| Placebo | DRUG | Placebo |
| MDX-1100 (anti-CXCL10 human monoclonal antibody) | DRUG | Patients will receive a single dose of MDX-1100 at 0.3, 1.0, 3.0 or 10 mg/kg as a 60 minute intravenous infusion. Patients who respond to treatment may receive up to an additional 3 doses of MDX-1100. |
Inclusion Criteria: * Must meet the ACR criteria for RA * Must have active RA, characterized by at least 6 out of 66 swollen joints and 6 out of 68 tender joints, and at least 2 of the following: a serum C-reactive protein level greater than the upper limit of normal, an erythrocyte sedimentation r...
Top 20 of 28 competitors
MDX-1100 is an investigational drug being studied for ulcerative colitis and rheumatoid arthritis. It is a small molecule developed by Bristol-Myers Squibb Company (BMY). Clinical trials have evaluated it in patients with active ulcerative colitis and in combination with methotrexate for active rheumatoid arthritis.
MDX-1100 targets CXCL10, as indicated by the trial title 'Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis.' It is a human monoclonal antibody directed against CXCL10, a chemokine involved in inflammatory processes.
MDX-1100 is developed by Bristol-Myers Squibb Company, traded on the New York Stock Exchange under the ticker BMY. The company is conducting clinical research on this investigational drug for autoimmune indications.
MDX-1100 is in Phase 2 clinical development. One completed Phase 2 trial evaluated it in combination with methotrexate for rheumatoid arthritis, and a Phase 1 trial in ulcerative colitis has also been completed. It remains investigational and is not FDA approved.
MDX-1100 has been studied in two completed trials: NCT00295282, a dose-escalation study in patients with active ulcerative colitis (Phase 1, 24 participants), and NCT01017367, a Phase 2 study in combination with methotrexate for active rheumatoid arthritis (70 participants). Both trials are completed.
Yes, MDX-1100 is an anti-CXCL10 human monoclonal antibody. This is confirmed by the official trial title for the rheumatoid arthritis study, which describes MDX-1100 as an anti-CXCL10 human monoclonal antibody. It is being investigated for its role in inflammatory conditions.